Introduction
A deprived microbial exposure may underlie the increase of allergic diseases in affluent countries (1, 2) . Probiotics are live micro-organisms which upon ingestion have been shown to exert health benefits in clinical studies, and it has been hypothesised that probiotics may reduce the risk for allergic disease (3) . Indeed, there are several double-blind placebocontrolled studies reporting a lower incidence of eczema until two years of age after oral supplementation with probiotics during the perinatal period and infancy (3) . According to the atopic march theory, eczema and food allergy are typically outgrown and replaced in school age by allergic asthma and rhinoconjuntivitis (4) . Consequently, it was expected that the probiotic treated children in these trials would have less respiratory allergic disease when they reached school age. The results of the first two follow ups, however, have been discouraging (5, 6) . Despite a much lower eczema incidence at two years of age in the Lactobacillus GG (LGG) treated infants compared to the placebo group, 23% vs. 46% (7), there were no effect on respiratory disease at seven years of age (5) . Furthermore, LGG intake did not influence sensitization rates ate any age (5, 7) . The asthma prevalence even tended to be higher in the LGG than the placebo group, 17% vs. 5%. Neither was there any effect on respiratory allergic disease in the 5-year follow up in a second prevention trial evaluating a mixture of prebiotics and five different probiotic strains (6) . In a clinical trial in New Zealand, in which a L. rhamnosus strain was tested, however, although there was no effect on sensitisation at two years (8) , the prevalence of rhinoconjunctivitis was lower in the probiotic than the placebo group at the 4-year follow up (9) .
Possibly, the lack of effect on IgE-mediated sensitisation in infancy in these studies (7, 10) could provide clues to the loss of power. Although IgE-mediated sensitisation is a common feature in eczema, recent articles suggest that IgE-mediated reactions are only part of a much more complex immunological picture in eczema (11) . The predictive value of nonIgE-associated eczema for subsequent asthma is also low. Approximately 14% of the nonsensitised infants with eczema develop asthma in school age compared with 60% of the sensitised infants with eczema (12).
In contrast to the probiotic strains in the other studies (3), Lactobacillus reuteri ATCC 55730 had an effect on sensitisation measures in infancy in a prevention study previously reported by us (13) . Although a similar eczema incidence was observed in the L. reuteri and placebo group until two years of age, the prevalence of IgE-associated eczema, 8% vs, 20% (13) , and the cumulative incidence of IgE-associated allergic disease, 20% vs. 35% (14) , were lower in the L. reuteri than in the placebo treated infants. Also, skin prick test (SPT) reactivity was less common in the L. reuteri than in the placebo group, significantly so for infants with allergic mothers, 14% vs. 31% (13) . We therefore hypothesised that the L. reuteri treated infants would run a reduced risk to develop later respiratory allergic disease. The aim of the present study was to evaluate whether perinatal and infant supplementation with L. reuteri reduced the prevalence of asthma and allergic rhinoconjunctivitis in early school age.
Methods

Study design
This was a follow up study at seven years of infants completing a randomised double-blind placebo-controlled trial evaluating the effect of L. reuteri on allergic disease and sensitisation until two years of age (13) reuteri and 26% in placebo group reported to have taken probiotics (any probiotic strain) during the last month (p=0.30). The baseline characteristics of the participating children are displayed in Table 1 . The study is registered at ClinicalTrials.gov (NCT01285830). A written informed consent was obtained from both parents before inclusion. The Regional Ethics
Committee for Human Research at Linköping University approved the study (M171-07).
Clinical investigations
Follow-up was performed by research nurses at seven years of age (± 3 months). Before the visit the parents completed a questionnaire based on the ISAAC questionnaire for 6-7 year old children (http://isaac.auckland.ac.nz/Index.html), supplemented with questions regarding gastrointestinal symptoms, antibiotic and probiotic intake the last months, family size, pets and parental smoking ( Table 1 ). The visits included structured interviews related to symptoms of allergic disease, physical examination, spirometry and measurement of fractional exhaled nitric oxid (FE NO ). The SCORAD index was used to assess the severity of the eczema (16). Histamine hydrochloride (10 mg/ml) was used as positive and albumin diluent as negative control. The test was regarded as positive if the mean diameter of the wheal was >3mm.
Diagnostic criteria
The primary outcomes at seven years of age were allergic disease and skin prick test suggested by Hanifin and Rajka (19) . Eczema was classified as IgE-associated if the infant had also a positive skin prick test.
Statistical analysis
The X 2 test was used to compare the prevalence of outcome variables and background factors between the groups. Fisher's exact test was used when the expected frequency for any cell was less than five. Logistic regression was employed for adjustment for possible confounders.
Continuous variables were analysed with student's t-test. As SCORAD scores and spirometry and FE NO values were not normally distributed, the groups were compared using MannWhitney U test for these analyses. A probability level of <0.05 was considered to be statistically significant. The calculations were performed using the statistical package IBM SPSS Statistics 20 (IBM Corp, NY, USA)
Results
The prevalence of asthma, allergic rhinoconjunctivitis, eczema and skin prick test reactivity was similar in the probiotic and placebo group (Table 2) . Neither were there any significant differences in the compound variables allergic disease and respiratory allergic disease between the treatment groups. The prevalence of children with IgE-associated eczema, in this study defined as SPT positive children with eczema, was also similar. The positive predictive value of IgE-associated eczema in infancy was only 33% for asthma and 39% for allergic rhinoconjunctivitis at seven years of age (Supplementary Table 1 ).
In the original study, the effect of L. reuteri treatment on SPT reactivity was stronger when only infants with mother with allergic diseases were included (13) . No such effect was seen at seven years of age. Thus, the prevalence of positive SPT was 18% and 20% in the L. reuteri and placebo group, respectively, after such stratification. Neither did stratification according to delivery mode, asthma heredity and probiotic intake during the last month affect the result (data not shown). Antibiotic prescription during the first year of life was more common in the L. reuteri than the placebo group (Table 1) , and boys had asthma more often than girls at seven years of age, 21% (20/96) vs. 9% (8/88), p=0.03. Adjustment for these variables, however, did not affect any comparison between the treatment groups.
The spirometry and exhaled nitric oxide (FE NO ) levels were similar in the two treatment groups ( Table 2 ). The FE NO levels were also similar between children with and without asthma (data not shown), although pathological levels (>20 ppb) were more common in children with asthma, 24% (5/21) vs. 2% (2/117), p=0.001. There were no differences in growth indices (Table 3) , nor in the prevalence of gastrointestinal symptoms between the treatment groups (Table 1) . No severe adverse events were reported.
Discussion
The effect of Lactobacillus reuteri on sensitisation and IgE-associated eczema in infancy (13) did not lead to a lower prevalence of respiratory allergic disease in school age. The lack of effect on these manifestation is consistent with previous follow ups with other probiotic strains (5, 6, 20) . The difference in sensitisation between the probiotic and placebo group at two years (13) was also gone at seven years of age. Thus, the effect of L. reuteri on the immune system seems to be transient. Since the number of children delivered with ceasarean section was low, the effect of probiotics in this subgroup in a previous follow up study (6) could not be properly evaluated.
Our results are consistent with the findings that L. reuteri colonisation at birth only decreased Th2-and increased Th1-associated chemokines at six months of age and not later (14) . Why the effect was transient is unclear. As only infants with confirmed L. reuteri colonisation and not all those who were treated with L. reuteri had a low Th2/Th1 chemokine ratio (14) , the dose (10 8 bacteria/day) might have been too low for a permanent immunological effect. The colonisation of L. reuteri was also transient (15) , with no persistent effect on the gut microbiota (2). Furthermore, the action of L. reuteri that resulted in less sensitisation in infancy and the mechanisms underlying eczema and asthma in school age may be separate phenomena. We have observed immunomodulatory effects on allergen-induced cytokine responses in probiotic treated infants that were not related to atopic disease development, indicating independent effects (21). An alternative explanation for the absent effect on sensitisation at seven years could be a false positive result in the two-year follow, despite the double-blind randomised-controlled design (13) . The effect on atopy remained after adjustments for possible confounders, however, reducing the risk of a false positive result (13) . The lack of blinding of the participants and assessors could theoretically have affected the result at seven years of age as well.
If prenatal microbial exposure is vital for a sustained preventive effect, as suggested by epidemiological (22, 23) and experimental (24, 25) In parallel with the lack of effect on the immune system, there were no signs of any long-term side effects in this follow up until school age. Thus, there were no indications of higher prevalence of allergic disease, no reports of severe side effects, and growth indices were similar in the probiotic and placebo groups. This is an important notion, since there have been concerns about treatment of vulnerable newborns and that the follow up period has been too short, often only until two years of age (3).
In conclusion, the effect of L. reuteri on sensitisation and IgE-associated eczema in infancy did not lead to a lower prevalence of respiratory allergic disease in school age. The effect of L. reuteri on the immune system seems to be transient. Administration of Lactobacillus reuteri perinatally was not associated with any long-term side effects until school age.
